Is there a difference in uptake of Paliperidone Palmitate between the deltoid and ventrogluteal injection sites?

This study examines if there is a difference in uptake of Paliperidone Palmitate (Sustenna) between the deltoid (arm) and ventrogluteal (hip) injection sites.

Age range 

16 to 65 years

Gender 

Male and Female

Individuals are eligible if they

  • Are a current inpatient, outpatient or day program patient of the Schizophrenia Recovery Program;
  • Have a schizophrenia spectrum illness;
  • Are receiving Paliperidone/Sustenna long-acting injection for the first time (or have been off Paliperidone/Sustenna for more than 6 months);
  • Are able to speak and understand English;
  • Are able to provide consent

Individuals are not eligible if they

  • Are currently on Risperidone/Consta long-acting IM or have been on it in the last 8 weeks;
  • Have presence of renal and/or hepatic impairment

Location

The Royal's Institute of Mental Health Research, affiliated with the University of Ottawa
1145 Carling Ave, Ottawa, ON

Recruitment Via

  • Internal Referral

Principal Investigator 

David Attwood, MD

Contact    

Lisa Murata
+1 (613) 722-6521 ext. 6679
lisa.murata@theroyal.ca

*This study is currently recruiting participants